RT Journal Article
SR Electronic
T1 Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.31.22275010
DO 10.1101/2022.05.31.22275010
A1 Costa Clemens, Sue Ann
A1 Milan, Eveline Pipolo
A1 Sprinz, Eduardo
A1 Neto, José Cerbino
A1 Pacciarini, Filippo
A1 Li, Ping
A1 Chen, Hui-Ling
A1 Smolenov, Igor
A1 Pollard, Andrew
A1 Clemens, Ralf
YR 2022
UL http://medrxiv.org/content/early/2022/06/02/2022.05.31.22275010.abstract
AB Background Ongoing outbreaks of COVID-19 are driven by waning immunity following primary immunizations and emergence of new SARS-CoV-2 variants which escape vaccine-induced neutralizing antibodies. It has been suggested that heterologous boosters could enhance and potentially maintain population immunity.Methods We assessed immunogenicity and reactogenicity of booster doses of different formulations of alum-adjuvanted SCB-2019 vaccine (9 μg SCB-2019 with or without CpG-1018 adjuvant, or 30 μg SCB-2019 with CpG-1018) in Brazilian adults primed with ChAdOx1-S vector vaccine. S-protein antibodies and ACE2-binding inhibition were measured by ELISA on Days 1, 15 and 29. Participants self-reported solicited adverse events and reactions.Results All SCB-2019 formulations increased S-protein ELISA antibodies and ACE2 binding inhibition to a greater extent than ChAdOx1-S. After 30 μg SCB-2019+CpG+alum titers against wild-type S-protein were significantly higher than after ChAdOx1-S on Days 15 and 29, as were titers of neutralizing antibodies against wild-type strain and Beta, Gamma, Delta, and Omicron variants. Boosting with SCB-2019 or ChAdOx1-S was well tolerated with no vaccine-related serious or severe adverse events.Conclusions Boosting ChAdOx1-S-primed adults with SCB-2019 induced higher levels of antibodies against a wild-type strain and SARS-CoV-2 variants than a homologous ChAdOx1-S booster, highest responses being with the 30 μg SCB-2019+CpG+alum formulation.Competing Interest StatementFP, PL, IE, H-LC, and IS are all full-time employees of the study sponsor. SACC and RC are scientific advisors to the study sponsor. EPM, ES, JCN and AP declare they have no conflicts to declare.Clinical TrialNCT05087368Funding StatementThe study was sponsored by Clover Biopharmaceuticals Inc. and was supported by grant from Bill & Melinda Gates Foundation (BMGF), No. INV-030336.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical review committee of the Centro de Estudos e Pesquisa em Molestias Infecciosas (CEPCLIN), Natal, Brazil approved this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors subject to prior publication of the manuscript in a peer-reviewed journal.